Filtered By:
Therapy: Endocrine Therapy
This page shows you your search results in order of date. This is page number 7.
Order by Relevance | Date
Total 2859 results found since Jan 2013.
Safety and Feasibility of CDK4/6 Inhibitors Treatment Combined with Radiotherapy in Patients with HR-positive/HER2-negative Breast Cancer A Systematic Review and Meta-analysis
CONCLUSION: The findings of this study suggest that radiotherapy in addition to CDK4/6i treatment in breast cancer patients is generally safe and well tolerated and remains a viable treatment option.PMID:37536378 | DOI:10.1016/j.radonc.2023.109839
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - August 3, 2023 Category: Radiology Authors: Marcin Kubeczko Micha ł Jarząb Dorota Gabry ś Aleksandra Krzywon Alexander J Cortez Amy J Xu Source Type: research
A Systematic Review and Meta-Analysis of Interventions to Promote Adjuvant Endocrine Therapy Adherence Among Breast Cancer Survivors
CONCLUSION: To our knowledge, this is the first known meta-analysis to demonstrate a significant effect for interventions to promote AET adherence. The systematic review revealed that lowering medication costs and a subgroup of psychosocial and reminder interventions showed the most promise, informing future research, policy, and clinical directions.PMID:37531593 | DOI:10.1200/JCO.23.00697
Source: Clinical Breast Cancer - August 2, 2023 Category: Cancer & Oncology Authors: Emma E Bright Lauren B Finkelstein Madeline S Nealis Sarah R Genung Jordan Wrigley Heng Chao J Gu Sarah J Schmiege Joanna J Arch Source Type: research
Real-World Predictors of Severe Neutropenia Associated with Palbociclib and Endocrine Therapy for Metastatic Breast Cancer in Japanese Patients
Biol Pharm Bull. 2023;46(8):1105-1111. doi: 10.1248/bpb.b23-00187.ABSTRACTTherapy for patients of metastatic breast cancer based on palbociclib, a cyclin-dependent kinase 4/6 inhibitor, has been approved in Japan. However, the risk factors for palbociclib-induced severe neutropenia in Japanese patients are rarely reported. Hence, the present study is aimed to identify the risk factors for adverse events requiring palbociclib dose reduction or discontinuation, and to identify the factors necessary to identify a more stable strategy for treatment continuation. This retrospective cohort analysis included patients with advance...
Source: Biological and Pharmaceutical Bulletin - August 2, 2023 Category: Drugs & Pharmacology Authors: Shinya Takada Hideki Maeda Kengo Umehara Sayuri Kuwahara Mitsugu Yamamoto Nobumoto Tomioka Kenichi Watanabe Kozo Mino Source Type: research
A Systematic Review and Meta-Analysis of Interventions to Promote Adjuvant Endocrine Therapy Adherence Among Breast Cancer Survivors
CONCLUSION: To our knowledge, this is the first known meta-analysis to demonstrate a significant effect for interventions to promote AET adherence. The systematic review revealed that lowering medication costs and a subgroup of psychosocial and reminder interventions showed the most promise, informing future research, policy, and clinical directions.PMID:37531593 | DOI:10.1200/JCO.23.00697
Source: Clinical Genitourinary Cancer - August 2, 2023 Category: Cancer & Oncology Authors: Emma E Bright Lauren B Finkelstein Madeline S Nealis Sarah R Genung Jordan Wrigley Heng Chao J Gu Sarah J Schmiege Joanna J Arch Source Type: research
Real-World Predictors of Severe Neutropenia Associated with Palbociclib and Endocrine Therapy for Metastatic Breast Cancer in Japanese Patients
Biol Pharm Bull. 2023;46(8):1105-1111. doi: 10.1248/bpb.b23-00187.ABSTRACTTherapy for patients of metastatic breast cancer based on palbociclib, a cyclin-dependent kinase 4/6 inhibitor, has been approved in Japan. However, the risk factors for palbociclib-induced severe neutropenia in Japanese patients are rarely reported. Hence, the present study is aimed to identify the risk factors for adverse events requiring palbociclib dose reduction or discontinuation, and to identify the factors necessary to identify a more stable strategy for treatment continuation. This retrospective cohort analysis included patients with advance...
Source: Biological and Pharmaceutical Bulletin - August 2, 2023 Category: Drugs & Pharmacology Authors: Shinya Takada Hideki Maeda Kengo Umehara Sayuri Kuwahara Mitsugu Yamamoto Nobumoto Tomioka Kenichi Watanabe Kozo Mino Source Type: research
